CARL · XBRL financial data

Carlsmed financial statements, every quarter

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (CARL's year ends in late December)

In thousands of dollars	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cost of revenue	3,214	3,147	3,557*	3,691	4,398
Gross profit	8,869	9,927	—	12,425	14,542
Research and development	4,160	4,445	5,264*	5,178	6,040
General and administrative	3,342	4,907	4,853*	6,226	7,618
Total operating expenses	15,371	18,962	20,926*	21,701	25,578
Operating income (loss)	(6,502)	(9,035)	(9,318)*	(9,276)	(11,036)
Interest income	336	954	1,028*	891	839
Interest expense	363	380	330*	311	313
Other income (expense)	(264)	509	705*	580	526
Income tax expense (benefit)	0	0	0*	0	0
Net income (loss)	(6,766)	(8,526)	(8,613)*	(8,696)	(10,510)
Earnings per share, basic USD per share	(1.47)	(0.40)	—	(0.32)	(0.39)
Earnings per share, diluted USD per share	(1.47)	(0.40)	—	(0.32)	(0.39)
Weighted average shares, basic thousands of shares	4,590	21,081	—	26,836	27,191
Weighted average shares, diluted thousands of shares	4,590	21,081	—	26,836	27,191

Fiscal quarters (CARL's year ends in late December)

In thousands of dollars	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	33,472	115,373	85,793	73,016	46,244
Short-term investments	—	—	24,000	24,000	24,000
Accounts receivable	9,711	11,296	11,362	12,268	13,775
Inventory	1,068	1,340	1,845	2,063	2,275
Prepaid and other current assets	1,841	3,356	3,573	3,959	4,224
Total current assets	46,192	131,465	126,673	115,406	109,598
Property and equipment, net	972	1,187	1,487	1,597	2,400
Right-of-use asset	2,144	1,986	1,826	1,663	5,951
Total assets	53,270	134,863	130,120	118,769	118,202
Accounts payable	2,581	2,672	4,481	2,952	3,704
Accrued liabilities	3,219	3,186	3,287	3,202	4,113
Total current liabilities	9,484	10,928	14,280	9,715	12,397
Lease liability, non-current	1,705	1,513	1,316	1,115	5,832
Total liabilities	27,614	28,203	31,251	26,521	33,956
Accumulated deficit	(83,666)	(92,192)	(100,805)	(109,501)	(120,011)
Total stockholders' equity	(83,073)	106,660	98,869	92,248	84,246
Total liabilities and equity	53,270	134,863	130,120	118,769	118,202
Common shares outstanding (cover page) thousands of shares	26,581	26,593	26,732	27,185	27,303

Fiscal quarters (CARL's year ends in late December)

In thousands of dollars	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(6,766)	(8,526)	(8,613)*	(8,696)	(10,510)
Stock-based compensation	258*	704*	790*	1,629	2,271*
Depreciation and amortization	61*	82*	98*	99	130*
Net cash from operating activities	(7,042)*	(8,459)*	(5,321)*	(13,007)	(7,358)*
Purchases of property and equipment	327*	159*	73*	79	121*
Net cash from investing activities	(672)*	(343)*	(24,230)*	(206)	(19,657)*
Net cash from financing activities	(2,246)*	90,703*	(29)*	436	243*

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Carlsmed	46,244	not reported	(7,358)*	27.3M	9.5 quarters	Q2 FY26 10-QJun 30, 2026
Alpha Pro Tech	18,901	not reported	2,213*	10.2M	—	Q2 FY26 10-QJun 30, 2026
TELA Bio	30,424	19,291	(9,381)*	44.9M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Pro Dex	11,759	20,560	6,490	3.2M	—	Q1 FY27 10-QSep 30, 2026
Shoulder Innovations	24,460	17,175	(7,392)*	20.8M	13.4 quarters	Q2 FY26 10-QJun 30, 2026
AVITA Medical	9,139	21,702	(3,496)*	30.9M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Pulmonx	55,843	22,756	(5,214)*	42.9M	10.7 quarters	Q2 FY26 10-QJun 30, 2026
NeuroPace	12,538	22,826	(3,903)*	34.3M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
CVRx	64,586	15,705	(8,826)*	26.6M	7.3 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.